You are here: Industry Insights > Allergan

News List

US regulators permit AbbVie/Allergan merger pharmatimes
May 06, 2020
AbbVie's plans to acquire Allergan have been cleared by the US Federal Trade Commission (FTC).
Botox gets license update in UK pharmatimes
March 27, 2020
Allergan has received a license update for Botox (botulinum toxin type A) in the UK, clarifying that appropriately trained and qualified healthcare professionals.
AbbVie, Allergan megamerger set for May close pharmatimes
March 23, 2020
AbbVie has released an update on its pending acquisition of Allergan, announcing that the companies have entered into a consent decree agreement with staff of the US Federal Trade Commission (FTC) regarding the deal.
Ten drugs in pre-registration phase have potential to reach blockbuster status by 2025: GlobalData expresspharma
March 13, 2020
Amgen and Allergan’s biosimilar candidate to Roche’s Rituxan (rituximab) shows the greatest potential of these drugs.
Allergan to fork over a hefty $300M to wrap pay-for-delay suit fiercepharma
January 07, 2020
With AbbVie and Allergan almost ready to wrap up their $63 billion megamerger, both drugmakers are looking to clear any outstanding accounts before the deal closes. And Allergan just agreed to fork over $300 million to resolve one of them.
Three more companies raise their US drug list prices europeanpharmaceuticalreview
January 07, 2020
Novartis, Merck and Allergan have joined numerous other pharmaceutical companies by increasing the price of certain drugs since the start of 2020.
Allergan scores year-end CGRP nod for migraine med Ubrelvy fiercepharma
December 31, 2019
The CGRP migraine prevention field already has three meds from Amgen, Eli Lilly and Teva vying for market share, and now Allergan has scored the first approval for an oral CGRP to treat migraines as they happen.
Amgen, Allergan Submit BLA for Biosimilar Candidate americanpharmaceuticalreview
December 23, 2019
Amgen and Allergan announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab).
AbbVie's premium bid for Allergan isn't enough for one investor, who's suing to block it fiercepharma
September 26, 2019
AbbVie agreed to buy Allergan in June, offering $188 per share, or a 45% premium to the company's shares at the time. It was a price and a deal that analysts assessed as a boon for Allergan shareholders.
Endo and Allergan settle opioid case ahead of trial europeanpharmaceuticalreview
September 04, 2019
The two pharma companies have agreed to pay $15 million to certain Ohio counties before an opioid abuse trial to be held in October.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page